UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance

Journal of Clinical Microbiology, 2008-01, Vol.46 (1), p.150-156

2008

Volltextzugriff (PDF)

In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare Candida Species as Determined by CLSI Broth Microdilution Methods

Journal of Clinical Microbiology, 2009-10, Vol.47 (10), p.3170-3177

2009

Volltextzugriff (PDF)

Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Aspergillus Species to the Triazoles

Journal of Clinical Microbiology, 2011-02, Vol.49 (2), p.586-590

2011

Volltextzugriff (PDF)

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp

Journal of Clinical Microbiology, 2010-01, Vol.48 (1), p.52-56

2010

Volltextzugriff (PDF)

Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin

Journal of Clinical Microbiology, 2011-02, Vol.49 (2), p.624-629

2011

Volltextzugriff (PDF)

Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007

Journal of Clinical Microbiology, 2009-10, Vol.47 (10), p.3185-3190

2009

Volltextzugriff (PDF)

In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method

Journal of Clinical Microbiology, 2009-10, Vol.47 (10), p.3323-3325

2009

Volltextzugriff (PDF)

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution

Journal of Clinical Microbiology, 2011-02, Vol.49 (2), p.630-637

2011

Volltextzugriff (PDF)

In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance

Journal of Clinical Microbiology, 2006-03, Vol.44 (3), p.760-763

2006

Volltextzugriff (PDF)

In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species

Journal of Clinical Microbiology, 2008-08, Vol.46 (8), p.2568-2572

2008

Volltextzugriff (PDF)

Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance Program

Journal of Clinical Microbiology, 2011-04, Vol.49 (4), p.1274-1279

2011

Volltextzugriff (PDF)

In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole

Journal of Clinical Microbiology, 2005-11, Vol.43 (11), p.5425-5427

2005

Volltextzugriff (PDF)

Contamination of health-care workers' hands with Escherichia coli and Klebsiella species after routine patient care: a prospective observational study

Clinical microbiology and infection, 2020-06, Vol.26 (6), p.760-766

2020

Volltextzugriff (PDF)

Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004)

Journal of Clinical Microbiology, 2005-05, Vol.43 (5), p.2163-2167

2005

Volltextzugriff (PDF)

Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance Program

Journal of Clinical Microbiology, 2008-11, Vol.46 (11), p.3585-3590

2008

Volltextzugriff (PDF)

Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values

Journal of Clinical Microbiology, 2011-03, Vol.49 (3), p.845-850

2011

Volltextzugriff (PDF)

Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002

Journal of Clinical Microbiology, 2004-07, Vol.42 (7), p.3142-3146

2004

Volltextzugriff (PDF)

Comparison of the Broth Microdilution Methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for Testing Itraconazole, Posaconazole, and Voriconazole against Aspergillus Isolates

Journal of Clinical Microbiology, 2011-03, Vol.49 (3), p.1110-1112

2011

Volltextzugriff (PDF)

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

Diagnostic microbiology and infectious disease, 2004-03, Vol.48 (3), p.201-205

2004

Volltextzugriff (PDF)

Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001

Journal of Clinical Microbiology, 2003-04, Vol.41 (4), p.1440-1446

2003

Volltextzugriff (PDF)

Global Surveillance of In Vitro Activity of Micafungin against Candida: a Comparison with Caspofungin by CLSI-Recommended Methods

Journal of Clinical Microbiology, 2006-10, Vol.44 (10), p.3533-3538

2006

Volltextzugriff (PDF)

Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp

Journal of Clinical Microbiology, 2006-02, Vol.44 (2), p.324-326

2006

Volltextzugriff (PDF)

Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program

Journal of Clinical Microbiology, 2008-02, Vol.46 (2), p.551-559

2008

Volltextzugriff (PDF)

Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods

Journal of Clinical Microbiology, 2007-01, Vol.45 (1), p.70-75

2007

Volltextzugriff (PDF)

In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from Blood

Journal of Clinical Microbiology, 2003-01, Vol.41 (1), p.78-83

2003

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Englisch
(94)
Japanisch
(12)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(69)
Life Sciences & Biomedicine
(66)
Humans
(58)
Biological And Medical Sciences
(55)
Microbiology
(55)
Fundamental And Applied Biological Sciences. Psychology
(45)
Mycology
(43)
Antifungal Agents - Pharmacology
(42)
Infectious Diseases
(36)
Miscellaneous
(34)
Candida - Drug Effects
(33)
Medical Sciences
(33)
Microbial Sensitivity Tests
(28)
Drug Resistance, Fungal
(22)
Triazoles - Pharmacology
(21)
Fluconazole - Pharmacology
(20)
Candida - Isolation & Purification
(19)
Candida
(18)
Candidiasis - Microbiology
(18)
Microbial Sensitivity Tests - Methods
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance

In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare Candida Species as Determined by CLSI Broth Microdilution Methods

Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Aspergillus Species to the Triazoles

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp

Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin

Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007

In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution

In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance

In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species

Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance Program

In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole

Contamination of health-care workers' hands with Escherichia coli and Klebsiella species after routine patient care: a prospective observational study

Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004)

Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance Program

Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values

Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002

Comparison of the Broth Microdilution Methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for Testing Itraconazole, Posaconazole, and Voriconazole against Aspergillus Isolates

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001

Global Surveillance of In Vitro Activity of Micafungin against Candida: a Comparison with Caspofungin by CLSI-Recommended Methods

Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp

Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program

Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods

In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from Blood

Suchergebnisse filtern